

Published in final edited form as:

J Neuroendocrinol. 2013 November ; 25(11): 1196–1208. doi:10.1111/jne.12066.

The implication of neuroactive steroids in Tourette syndrome pathogenesis: a role for 5 α -reductase?

Marco Bortolato¹, Roberto Frau², Sean C Godar¹, Laura J Mosher¹, Silvia Paba³, Francesco Marrosu³, and Paola Devoto²

¹Dept. of Pharmacology and Toxicology, School of Pharmacy; University of Kansas, Lawrence (KS), USA

²Dept. of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato (CA), Italy

³Dept. of Public Health, Clinical and Molecular Medicine, Section of Neurology, University of Cagliari, Monserrato (CA), Italy

Abstract

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by recurring motor and phonic tics. The pathogenesis of TS is thought to reflect dysregulations in the signaling of dopamine (DA) and other neurotransmitters, which lead to excitation/inhibition imbalances in cortico-striato-thalamocortical circuits. The causes of these deficits may reflect complex gene \times environment \times sex (G \times E \times S) interactions; indeed, the disorder is markedly predominant in males, with a male-to-female prevalence ratio of \sim 4:1. Converging lines of evidence point to neuroactive steroids as likely molecular candidates to account for G \times E \times S interactions in TS. Building on these premises, our group has begun examining the possibility that alterations in the steroid biosynthetic process may be directly implicated in TS pathophysiology; in particular, our research has focused on 5 α -reductase (5 α R), the enzyme catalyzing the key rate-limiting step in the synthesis of pregnane and androstane neurosteroids. In clinical and preclinical studies, we found that 5 α R inhibitors exerted marked anti-DAergic and tic-suppressing properties, suggesting a central role for this enzyme in TS pathogenesis. Based on these data, we hypothesize that enhancements in 5 α R activity in early developmental stages may lead to an inappropriate activation of the “backdoor” pathway for androgen synthesis from adrenarche until the end of puberty. We predict that the ensuing imbalances in steroid homeostasis may impair the signaling of DA and other neurotransmitters, ultimately resulting in the facilitation of tics and other behavioral abnormalities in TS.

Introduction

Tourette syndrome (TS) is a neurobehavioral condition characterized by recurring motor and phonic tics during childhood and adolescence. The bulk of evidence suggests that tics are the phenotypic correlate of the activation of ectopic foci in the basal ganglia, due to excitation/inhibition imbalances in cortico-striato-thalamocortical (CSTC) connections [1]. The neurobiological bases of these impairments are likely multifactorial and may reflect the molecular interplay of a broad set of genetic, environmental and gender-related variables [2]. Notably, male gender and exposure to psychosocial stress have been highlighted as key risk factors for TS pathogenesis, indicating that androgens and other neuroactive steroids

may directly participate in the pathophysiology of this disorder. Although the neuroendocrinological alterations in TS have been the focus of little research to date, recent progress on the steroidogenic pathways may provide novel avenues to understand several critical aspects of TS pathophysiology. The present article will review the current state of the art on the implication of neuroactive steroids in TS. In particular, we will discuss our recent translational findings on 5 α -reductase (5 α R), the enzyme that catalyzes one of the key rate-limiting steps in the synthesis of neurosteroids and androgens. Based on emerging findings on a putative therapeutic potential of 5 α R inhibitors in TS, we will outline a hypothetical mechanism whereby alterations of this enzyme may contribute to the sex differences and stress sensitivity associated with TS.

Clinical features and pathophysiology of TS

TS is a familial, childhood-onset neurobehavioral disorder characterized by multiple motor tics and at least one phonic tic, with a duration greater than one year [3]. The prevalence of the disorder has been recently estimated between 0.4 and 1% of the population [4]. In addition to tics, approximately 90% of patients are affected by comorbid psychiatric conditions, including attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), as well as reactive aggression and other impulse-control disorders (ICDs) [5, 6].

Motor tics are sudden, involuntary, non-rhythmic movements, frequently confined to the head, neck, face and mouth muscles, but also observed in the trunk and limbs [7]. Phonic tics are rapid vocalizations due to rapid air movements through the upper respiratory tract, which can sometimes be associated with copro-, echo- or palilalia [8]. Tics can also be classified as simple or complex, based on the degree of involvement of different muscles. Simple tics are brief and repetitive actions, such as eye blinking, facial grimacing, head jerking, sniffing or grunting sounds; conversely, complex tics engage multiple muscle groups in coordinated and stereotyped patterns akin to purposeful activities, including touching objects or people, hopping and jumping as well as uttering words or phrases [9].

Tics are distinctively preceded or accompanied by premonitory urges and sensory phenomena; these intrusive, uncomfortable feelings are often described as a sense of inner tension associated with focal or generalized somatic sensations, and are commonly relieved by the execution of tics [10]. While most TS-affected individuals are able to temporarily suppress tics, the ensuing buildup of tension results in an increased sense of distress and in a greater urge to tic. The dynamics of these phenomena are similar to the neuropsychological sequence of OCD, in which compulsions are typically enacted as a maladaptive coping strategy to alleviate the anxiety associated with obsessive thoughts [11].

The typical onset of TS occurs at 6–7 years of age and is characterized by the appearance of simple, recurrent motor tics, followed by the manifestation of phonic tics after several months [12]. In most children, TS symptoms undergo a progressive exacerbation, which reaches its zenith at the beginning of puberty (11–12 years of age), and is then followed by a gradual remission in the majority of patients [13]; conversely, 30–40% of TS-affected children retain their symptoms in adulthood [14]. In addition to these temporal changes, tic severity exhibits numerous fluctuations throughout life and is typically increased during periods of high mental and physical stress [15].

Although the pathophysiological bases of TS remain partially unclear, converging lines of evidence have shown that the disorder is underpinned by functional and/or morphological impairments of the CSTC pathway. As mentioned above, numerous studies support that tics may arise from multiple, heterogeneous neurobiological deficits, which ultimately lead to general imbalances of the inhibitory and excitatory inputs within the striatum and the other

basal ganglia. Specifically, these imbalances may be related to the insufficient inhibitory tone from select families of striatal interneurons [16, 17] and/or the excessive striatal activation from the cortex or other brain regions (for a comprehensive review of this issue, see [1,2]). These impairments may lead to a disproportionate striatal stimulation and the activation of ectopic foci due to the inadequacy of center-surround interactions within this brain region [18].

Multiple neurotransmitters have been implicated in TS, including dopamine (DA), serotonin, norepinephrine, acetylcholine, glutamate and γ -amino-butyric acid (GABA) [19]. In particular, ample evidence supports the involvement of DAergic dysfunctions in TS. Tics are markedly reduced by DA receptor antagonists, such as haloperidol and pimozide [20], while they are exacerbated by DAergic agonists [21]. In addition, several neuroimaging and post-mortem studies have shown excessive activity and/or innervation of the cortex and basal ganglia of TS patients [22], which may reflect dysregulations in the DAergic system [23–26].

Recent studies indicate that the key DAergic impairment in TS may consist of a sharp contrast between low tonic and high phasic DA levels in the basal ganglia [27]. This background suggests that tics may be underpinned by rapid variations in synaptic DA content, leading to a prominent activation of postsynaptic D₁ receptors in the striatum. These receptors govern the activation of the “direct pathway” projections to globus pallidus and substantia nigra *pars reticulata*, and may therefore lead to the stimulation of ectopic foci. Accordingly, the initial results of a recent clinical trial sponsored by the Tourette Syndrome Association (TSA) suggest that the D₁ receptor antagonist ecopipam may be highly effective as a therapeutic option for TS [28].

It is worth noting that the implication of the DAergic system in the pathophysiology of TS may also involve the key role of this neurotransmitter in the ventral striatum with respect to the orchestration of critical behavioral functions, such as habit formation, incentive motivation, configuration of salience maps and sensorimotor gating [29–33]. Indeed, TS patients feature alterations in all these behavioral domains [34–37].

Etiology of TS: genetic, environmental and sex factors

Over the past decade, research into the etiology of TS has afforded fundamental contributions to our current understanding of the biological bases of this disorder. In particular, a large body of evidence has indicated that, similarly to other neuropsychiatric conditions, TS is a multifactorial disorder governed by multiple genetic, environmental and sex-related factors [38–40].

Genetic factors

The genetic basis of TS was originally postulated by several groups in the late 1970's, based on clinical observations on the high familiarity of the syndrome [41, 42]. These findings spurred a great number of analyses on genetic variants in TS. Specifically, some of the first genetic studies on TS focused on genes directly implicated in DA and serotonin regulation. Recently, several candidate genes have been discovered based on sporadic and familial mutations associated with TS (Table 1). Among these genes, particular interest has been recently raised by *SLITRK1* [43–45], which encodes for a molecule involved in the organization of neurite growth.

In addition to specific studies on select genes, recent whole-genome analyses have been conducted to identify potential single-nucleotide polymorphism (SNP) variants associated with TS. Recently, the TSA International Consortium for Genetics (TSAICG) reported the

results of the first genome-wide association study (GWAS) on TS, based on the analysis of 484,000 SNPs in the DNA of 1496 TS patients and 5249 controls [46]. Although the data revealed the possible association of TS with several genes, none of the identified SNPs reached the threshold of genome-wide significance, further confirming the complex genetic architecture of TS inheritance.

An alternative approach to study inheritance patterns in TS is afforded by genetic linkage studies across families with high TS prevalence. The largest linkage study for TS and tic disorder to date, also conducted by the TSAICG [47] on 238 nuclear families and 18 large multigenerational families totaling 2040 individuals, identified regions of high linkage to the disorder in the chromosome 2p23 [47, 48].

Environmental factors

TS pathogenesis is influenced by the exposure to several environmental variables [49]. The severity of tics and other behavioral symptoms in TS is typically exacerbated by the exposure to environmental and psychosocial stress [50–54]. For example, stressful contingencies lead to a reduced ability in suppressing tics [55]. The relation between TS and stress appears to be bidirectional, insofar as patients have higher stress perception than non-affected controls, and short-term future tic severity is predicted by current levels of psychosocial stress [56]. These findings underscore a critical involvement of stress-response mechanisms in TS pathogenesis.

In addition to the emotional impact of current contingencies, TS has been associated with the occurrence of several adverse events during pre- and perinatal stages [57–59], including maternal psychosocial stress [60] as well as severe nausea and vomiting during the first gestational trimester [60]. Maternal smoking and consumption of medications are also significant risk factors for the disorder [61]. Finally, exposure to infections (particularly from β -hemolytic streptococcus) has been associated with higher incidence of TS and associated syndromes [62]. The involvement of neuroinflammatory events in TS is suggested by numerous findings [63, 64], and may also reflect the involvement of autoimmune processes [65]. The exposure to prenatal complications (including infections) may indirectly influence the clinical course of TS by altering stress reactivity [66, 67].

Sex factors and gender differences in TS

One of the most striking epidemiological aspects of TS lies in its marked gender differences. Similarly to other neurodevelopmental conditions, such as ADHD and autism-spectrum disorder (ASD), male gender is a major risk factor for TS (with a male:female prevalence ratio estimated at ~4:1) [68]. Although the biological mechanisms underlying the higher TS vulnerability in boys remain elusive, genetic studies have clearly ruled out that this phenomenon may reflect the involvement of X-linked heritability patterns.

The implication of sex factors in TS is also indirectly indicated by the observation that temporal variations of tic severity are characteristically time-locked with all the major phases of sex maturation. For example, the typical age of onset coincides with adrenarche (6–7 years old); symptoms increase in severity until the beginning of puberty (12 years old) and then undergo a spontaneous amelioration, which becomes apparent with the end of puberty (at 18–19 years of age).

In males, TS onset is characterized by anger-related manifestations and simple tics; conversely, females exhibit complex tics more often than males. TS is diagnosed later in females than males, with different age distributions [69]; furthermore, recent data indicate that, while male gender increases vulnerability for tics in childhood, female gender may predict greater tic severity in adulthood [70]. Interestingly, male TS patients exhibit

significant deficits in cortical and callosal thickness, which are not observed in females [71–73].

Neuroactive steroids in TS

The epidemiological evidence outlined in the previous section suggests that the neural underpinnings of TS may result from complex GxExS interactions. Although the molecular bases of these putative interactions remain unknown, emerging data point to neuroactive steroids as primary candidates for the mediation of these mechanisms, given their well-characterized role in the regulation of stress responses and gender differences.

Sex steroids in TS

The first studies on endocrine changes in TS were published in the late 1980's, and suggested that this disorder may feature functional alterations in the secretion of luteinizing hormone (LH), the main regulator of gonadal androgen synthesis [74, 75]. In the following years, a number of clinical observations showed that tics in TS patients could be exacerbated by anabolic androgens [76]. In addition, TS patients were found to exhibit behavioral features typically associated with androgens, including aggressiveness, precocious sex drive and pervasive erotic urges [77, 78]. Furthermore, studies on the behavioral characteristics of TS-affected children have also assessed that tic severity correlates with their preference for masculine play, irrespective of gender [79].

One of the most intriguing aspects of the postulated involvement of male sex hormones in TS is the possibility that steroidogenic enzymes and androgen receptors may serve as putative therapeutic targets for this disorder. The androgen receptor antagonists flutamide and cyproterone were tested in adult TS patients with positive results [80–82]. In particular, flutamide (750 mg/day) was tested in a cross-over, double-blind, placebo-controlled trial with 10 men and 3 women affected by TS. Treatment was evaluated for 21 days, and resulted in a very modest (7%), yet significant amelioration of motor tic severity; conversely, no significant effects were observed on phonic tics and OCD symptoms [81]. Overall, the limited and short-lived efficacy of the drug undermined its therapeutic suitability, also in consideration of its potential severe hepatic side effects [83].

Unlike males, tic severity is typically increased after puberty in females. Preliminary surveys appeared to indicate that, in women, tic severity can be conditioned by variations in hormonal profile during the menstrual cycle. In particular, 26% of females were found to experience exacerbation of tics in the estrogenic phase of the menstrual cycle, and this phenomenon was found to be correlated with increased tic severity at menarche [84]. While these data clearly support direct implication of estrogens in TS pathogenesis, evidence in this respect remains limited and controversial. Indeed, in a different study, no significant correlation was found between fluctuation in tic severity and frequency and variations in estradiol or progesterone through the menstrual cycle in female TS patients [85].

Although the neurobiology of sex steroid involvement in TS is not clear, numerous animal studies have shown that sex hormones (including testosterone, estradiol and progesterone) yield multiple modulatory effects on DAergic responses in the striatum and nucleus accumbens [86–91].

Glucocorticoids in TS

The involvement of neuroactive steroids in TS is also postulated in view of the increased stress sensitivity of TS patients [92,93], which has been linked to alterations of the hypothalamic-pituitary-adrenal (HPA) axis and glucocorticoid receptor function. Indeed, abnormal functional enhancements of HPA axis were found in TS patients in response to

stressful medical procedures [94, 95] as well as injection of the opioid antagonist naloxone [96]. Furthermore, synthetic glucocorticoid treatment increased tics in two cases of tic disorders [97]. Several rodent studies suggest that glucocorticoids modulate brain DA levels [98, 99], underscoring the possibility that this neurotransmitter may be involved in the link between these neuroactive steroids and TS. It should be noted, however, that cortisol does not appear to play a prominent role in the variations in stress responsiveness in TS; indeed, Corbett and coworkers [93] did not identify significant differences in the natural cortisol circadian variations between TS-affected children and healthy probands. Further studies are required to ascertain the degree of implication of each major glucocorticoid hormone in the modulation of TS symptoms.

Steroid 5 α R: a putative candidate for GxExS interactions in TS

One of the least explored aspects of the involvement of steroids in TS concerns the existence of possible abnormalities in neurosteroidogenesis, i.e. the biosynthesis of steroids in the central nervous system, and, more specifically, in the brain. Over the past two decades, converging lines of research have elucidated that the brain and spinal cord synthesize multiple classes of endogenous steroids; these compounds act in coordination with the abundant endocrine input received from adrenal and gonadal steroids to regulate a broad set of neurobehavioral functions, including stress response and gender-related characteristics. Interestingly, various studies indicated that steroids endogenously produced in the nervous system and the regulation of neurosteroidogenesis by neurotransmitters represent pivotal processes to be considered with specific attention in the investigations aiming to clarify the mechanisms involved in various neural disorders [100, 101]. Although not all the details of neurosteroidogenic reactions have been fully elucidated, it has become clear that both the biosynthesis and metabolism of all major sex steroids can occur in the brain, through a number of tightly interwoven reactions (Fig.1).

Building on these premises, our research has been focused on the enzyme 5 α R, which subserves one of the key rate-limiting steps in the synthesis of neurosteroids. 5 α R catalyzes the saturation of the 4,5 double bond of the A ring of Δ^4 -3-ketosteroid substrates, such as deoxycorticosterone, progesterone, androstenedione and testosterone. This irreversible reaction is instrumental for the conversion of these compounds into their pregnane and androstane metabolites [102]. Among the many reactions catalyzed by 5 α R, it is important to note that this enzyme is essential for the synthesis of 3 α ,5 α -tetrahydroprogesterone (allopregnanolone, AP) and 3 α ,5 α -tetrahydrodeoxycorticosterone (THDOC), two neurosteroids directly implicated in the regulation of stress response through the positive modulation of the γ -amino-butyric acid (GABA)_A receptor in the brain [103]. In particular, it should be noted that THDOC has been recently shown to be the primary activator of the HPA axis in response to stress [104].

5 α R also catalyzes the conversion of testosterone into its metabolite 5 α -dihydrotestosterone (DHT), which is the most potent androgen hormone *in vivo* and orchestrates the development of male external genitalia and secondary sex traits. Indeed, 5 α R inhibitors have been developed specifically for the reduction of DHT levels, which has been shown to have therapeutic effects for benign prostatic hyperplasia and male-pattern alopecia [102].

Of the five types of 5 α R enzymes characterized to date, the first two (termed 5 α R1 and 5 α R2) play major roles in steroidogenesis and mediate overlapping reactions [102]; however, they differ by patterns of localization and expression. 5 α R1 is highly expressed in the epidermal cells, neurons and adrenal glands; conversely, 5 α R2 is predominantly expressed in the male urogenital tract, as well as genital skin, hair follicles and liver. While 5 α R2 is not as abundant as 5 α R1 in the brain, it can be found across most structures, and

particularly in the cortex and cerebellum [105]. The expression of 5 α R2 in the brain appears to be related to the surges in testosterone levels in this organ. In fact, the expression of this enzyme has been mainly documented in early developmental stages. In adults, the expression of the enzyme is posited to depend on androgens.

Although the reactions mediated by 5 α R1 and 5 α R2 are largely overlapping, it is interesting to notice that 5 α R2 has a higher affinity for progesterone and testosterone, possibly suggesting that these two isoenzymes may be differentially activated in the brain, in relation to different concentrations of substrates. Furthermore, unlike 5 α R1, 5 α R2 is distinctly absent from glial cells [105], likely signifying a topographical segregation of their functional roles.

Both 5 α Rs have been shown to play a role in stress response. Specifically, short-term stress increases the expression of these enzymes, thereby allowing the synthesis of neuroactive steroids. In the brain, the increased 5 α R activity leads to higher synthesis of AP, THDOC and other neurosteroids, which appear to modulate stress response through multiple mechanisms, including the direct regulation of HPA axis [104]. The best characterized of such mechanisms is the positive modulation of GABA_A receptor by AP; however, emerging data indicate that other 5 α -reduced neurosteroids may play a key role in the responses to stress. In addition, it should be noted that, while stress-induced increases in 5 α R activity have been well characterized in brain regions, recent data support that this phenomenon may also occur in peripheral organs, such as the prostate [106].

Behavioral properties of 5 α R inhibitors: preclinical studies

Our preclinical studies on 5 α R began with the evaluation of the anti-DAergic properties of its inhibitors finasteride and dutasteride in animal models. In particular, we originally observed that these agents could lead to a dramatic reduction of the deficits in sensorimotor gating induced by the non-selective DAergic agonists amphetamine and apomorphine [107]. Gating deficits, as measured in the paradigm of prepulse inhibition (PPI) of the acoustic startle reflex, have been shown to be highly relevant to the cognitive alterations described in TS [108]. PPI deficits are exhibited by TS patients [31, 109], and are posited to indicate the impaired ability to filter out irrelevant stimuli. This may be particularly relevant with respect to tics, which are generated in response to intrusive sensory phenomena [110–113]. Although finasteride exhibited anti-DAergic mechanisms similar to those elicited by haloperidol across several behavioral tasks, it strikingly failed to induce catalepsy [107]. Following these findings, we analyzed the neurobiological bases of the antipsychotic-like mechanisms of finasteride. In particular, we found that, in males, the effects of systemic finasteride were not affected by castration, and were mimicked by the intracerebral infusion of the drug in the nucleus accumbens [114]. Moreover, we recently found that, in mice, the mechanisms of finasteride are mediated by D₁ DA receptors [115]. This result is particularly noteworthy, in view of recent evidence supporting the therapeutic efficacy of D₁ receptor antagonists in TS [28].

Therapeutic properties of 5 α R inhibitors: clinical studies

Prompted by these preclinical results, we studied the therapeutic potential of finasteride in adult male TS patients. The first patient who gave informed consent for experimental treatment with finasteride as an adjunctive therapy was a severe case of TS with explosive vocalizations, stereotyped coprolalic utterances, self-injuring motor tics and excessive sex drive. Previous therapeutic attempts with typical antipsychotics had resulted in transient improvements, but the high rate of extrapyramidal and cognitive side effects had led him to repeated withdrawals [116]. Finasteride (5 mg/day) led to a gradual improvement of his motor and vocal tics, as assessed by the Yale Tic Severity Scale with no reported side

effects. The discontinuation of the regimen after 18 weeks, however, resulted in an abrupt, dramatic exacerbation of the symptoms, which was countered by reinstatement of the 5 α R inhibitor.

The therapeutic effects of finasteride as an adjunctive treatment in TS have been confirmed in a first open-label study with adult male patients, who exhibited a significant reduction of the severity of tics and associated compulsive (but not obsessive) manifestations by the sixth week of therapy [117]. At the time of this writing, the open trial of finasteride has been extended to 16 TS male adult patients. As shown in Fig.2, our patients consistently showed a fully significant reduction in tic severity by the 6th week of treatment, and reached a plateau in therapeutic effects by the 12th week of finasteride administration. Notably, three patients have shown that finasteride discontinuation led to a sudden exacerbation of their symptoms. Interestingly, in contrast with antipsychotics, finasteride does not elicit extrapyramidal side effects in patients [102, 117]. Our preliminary surveys on the psychological mechanisms of finasteride in tic suppression revealed that, in most patients, this drug confers an attenuation of the premonitory urges and a greater ability to control the execution of tics and other impulses, resulting in lower interference and higher functioning. In addition, our results seem to suggest that finasteride is more efficacious in reducing simple, rather than complex tics (manuscript in preparation). Following these results, our group has begun a double-blind, placebo-controlled clinical trial at the Tourette Syndrome Center of the University of Cagliari, Italy.

The idea that 5 α R inhibitors may reduce tic severity by improving impulse control is indirectly supported by our recent clinical observations on the effects of finasteride in ICDs. Indeed, we found that, in males, finasteride reduced pathological gambling induced by DA receptor agonists + levodopa in Parkinson's disease patients [118].

Studies are currently ongoing to advance our understanding of the potential mechanism of action of 5 α R in TS. Although the involvement of this enzyme in TS remains to be fully ascertained, the possibility that both 5 α R isoenzymes may be directly involved in the genetic bases of the disorder is supported by a number of observations.

Specifically, the largest linkage study for TS and tic disorder has identified a region of high linkage in the chromosome 2p23 [47, 48], in a position directly proximal to (or partially coinciding with) the gene *SRD5A2*, which encodes for 5 α R2 [119]. Furthermore, two previous TS genome scan studies pointed to chromosomal regions proximal to the gene *SRD5A1* (encoding for 5 α R1) on chromosome 5p15 [120, 121].

Interestingly, both genes exhibit a number of functional polymorphic variants. In particular, several studies have associated *SRD5A2* variants with neurodevelopmental disorders with higher incidence or severity in males, such as autism and schizophrenia [122, 123]. In particular, in the latter disorder, *SRD5A2* variations have been associated with increased cortisol metabolism [124].

The conundrum of the role of androgens in TS: is the key in the “back door”?

One of the most puzzling aspects about the involvement of endogenous androgens in TS pathophysiology is that the surge of gonadal androgens in the bloodstream during puberty typically coincides with a *reduction*, rather than an exacerbation, in tic severity. Interestingly, the hypothesized hyperactivity of 5 α R in TS may afford a possible solution to this conundrum, in view of the newly-discovered role of this enzyme as the gatekeeper of alternative steroidogenic pathways throughout different stages of sexual development.

As noted above, the median age of TS onset coincides essentially with adrenarche, the first stage of sexual maturation characterized by the development of the inner *zona reticularis* in the adrenal cortex. The biochemical hallmark of adrenarche is the acquisition of 17,20 lyase activity by cytochrome P450 C17 (CYP17A1) [125], which is promoted by cytochrome b5 and the phosphorylation of serine residues [126–132]. The result of this process is the increased synthesis of dehydroepiandrosterone (DHEA) and androstenedione, which leads to the growth of axillary and pubic hair as well as enhancement in the oiliness of the skin [133]. The increase in 17,20 lyase activity of CYP17A1 is instrumental for the activation of the Δ^5 pathway, the predominant route of androgen synthesis in puberty and adulthood [128, 134]. This pathway consists in the conversion of 17-OH-pregnenolone into DHT through four intermediate reactions, mediated by 17,20 lyase, 3 β -hydroxysteroid dehydrogenase (3 β -HSD), 17 β -hydroxysteroid dehydrogenase type 3 (17 β -HSD3) and 5 α R2 (Fig. 1).

Recent studies have documented the existence of an alternative “backdoor pathway” for the synthesis of DHT, which appears to be predominant before adrenarche. In this series of reaction, 17-OH pregnenolone is converted into 17-OH AP via the combined actions of 5 α R1 and 3 α -hydroxysteroid oxidoreductase (3 α -HSOR). Importantly, CYP17A1 exhibits a great affinity for 17-OH-AP, which is higher than that for 17-OH-pregnenolone [135, 136] and does not require the activation of cytochrome b5 for the acquisition of 17,20 lyase activity. This enzyme converts 17-OH AP into androsterone, which is then further metabolized into 3 α -androstane diol by 17 β -HSD and then into DHT by oxidative 3 α -HSOR [136]. The backdoor pathway has been recently demonstrated in humans [137] and is considered to play a key role in the production of DHT and other androstane derivatives in the developmental stages before adrenarche [138].

The shift from the backdoor pathway to the Δ^5 pathway is based on the functional antagonism between 5 α R and CYP17A1. The prevailing activity of 5 α R allows the predominance of the backdoor pathway, by facilitating the synthesis of 17-OH-AP. This premise suggests that 5 α R hyperactivation in the periphery may lead to the persistence of the backdoor pathway even after adrenarche; upon these conditions, we predict that the imbalance in androgens would lead to a persistent increase in androsterone, androstane diol and DHT, as well as a relative decrease in DHEA and androstenedione. Androstane derivatives exert their effects through a vast array of receptors, including farnesoid receptor (FRX), β -estrogen receptors, which may indeed contribute to lower the threshold for tics in the presence of other predisposing variables. Alternatively, it is even possible that the persistence of 5 α R2 throughout childhood may facilitate the conversion of androstenedione (which has high affinity for this isoenzyme) into androstane diol, which would then be reconverted into androsterone by 3 α -HSOR. Interestingly, we recently found that blockers of CYP17A1 exert anti-DAergic actions akin to those of finasteride (manuscript submitted).

The imbalances in androgenic steroids unmasked in adrenarche could be remedied in puberty, with the full activation of Δ^5 pathway due to LH. Indeed, gonadotropins stimulate testosterone production via the Δ^5 pathway, and may inhibit the backdoor pathway in the testicles [139]. Nevertheless, it should be noted that the mechanism of involvement of puberty in tic ontogenesis is likely more complex. Indeed, puberty may actually be conducive to tic exacerbation, rather than remission, as suggested by the relatively high occurrence of tic disorders in familial male precocious puberty [140]. Thus, it is likely that the phenotypic changes associated with puberty may also involve the relation between the alterations in steroid profile and other neurodevelopmental aspects, such as the maturation of the DAergic system etc.

Furthermore, we cannot exclude that the postulated mechanism may only be applicable in males, while different mechanisms may be present in girls, depending on the relevance of aromatization processes in the aforementioned mechanisms.

A key unresolved issue concerns the possible existence of a “backdoor pathway” (or its functional equivalent) in the brain, in addition to those already documented in the adrenal cortex and gonads. Notably, all the enzymes that are required for activation of the backdoor pathway are also expressed in brain regions, including 3 β -HSD, 5 α R, 3 α -HSD, CYP45017A1 and 17 β -HSD [141–149].

Conclusions and future perspectives

The findings and concepts delineated in this review suggest that neurosteroids may play a key role in the pathophysiology of TS, through multiple mechanisms including the modulation of DA neurotransmission and signaling.

An accurate evaluation of the role of neurosteroids in TS and other neuropsychiatric disorders is limited by numerous theoretical and practical obstacles. One of the main problems lies in the limited scope of most endocrinological analyses performed in neuropsychiatric disorders, which typically measure only a restricted number of endogenous steroids in plasma and/or urine. A possible solution for this limitation may be represented by new steroidomic techniques, based on the combination of charge tagging and liquid chromatography-tandem mass spectrometry. The utilization of these approaches, particularly if applied to CSF analyses, holds promise for a much more detailed understanding of the steroidal alterations in TS. Indeed, similar analyses have been recently conducted in healthy subject and have led to a series of surprising findings, such as an unexpected abundance of intermediate compounds of the bile biosynthetic pathways in the CSF [150]. These high-throughput strategies, together with large-scale epigenetic, transcriptomic and proteomic analyses, may prove fundamental to frame the role of neurosteroidogenesis in TS, and provide a rich sources for candidate therapeutic targets.

Our preclinical and clinical results support the possibility that 5 α R (and possibly other steroidogenic enzymes) are involved in the pathogenesis of TS. In particular, the newly-defined role of 5 α R as a “gatekeeper” of alternative steroidogenic pathways at the intersection of stress-activated metabolic responses and gender differences may afford a unitary platform to explain the mechanism of potential GxExS interactions in TS. Despite the limited side effects and good tolerability profile of finasteride, the clinical applications of finasteride on TS therapy remain limited; in fact, this drug cannot be used in children, who represent the broadest target population in this disorder. In addition, recent evidence has pointed to a number of severe, permanent side effects of finasteride in a small subset of male individuals (who were prescribed this drug as a therapy for hair loss), including depression, suicidal thoughts and impotence [151–153].

In spite of these limitations, the identification of the neurobiological bases of the effects of finasteride and other 5 α R inhibitors may point to novel avenues for the development of potential therapeutic tools for this disorder with limited endocrine side effects. The recent evidence that 5 α R inhibition interferes with some of the behavioral effects of D₁ receptors in animal models is highly promising [115], in view of emerging evidence of the relevance of this target in TS. Further studies are warranted to establish the molecular mechanisms of neurosteroid actions and their impact on DA and other neurotransmitter systems.

From this perspective, preclinical studies on animal models are essential as a tool to test mechanistic hypotheses on the contribution of steroids in TS pathogenesis, as shown by our translational research on finasteride and 5 α R inhibitors. Our studies on finasteride showed

that, despite potential differences between humans and rodents in steroidogenesis, the employment of animal models is an essential component for the enactment of effective translational strategies in TS. We are beginning to test the role of 5 α R in models of TS with high face, construct and predictive validity, such as the D1CT-7 mice [154,155]. In these transgenic animals, the promoter region for the D₁ receptor was fused with the enzymatic portion of cholera toxin subunit $\alpha 1$ (A1) gene, which leads to a persistent activation of Gs proteins. D1CT-7 mice display explosive jerking movements of the head, trunk and limbs, which are highly reminiscent of tics [156,157]. In conformity with the gender discrepancies in TS patients, D1CT-7 male mice exhibit more tic flurries than females. Furthermore, the onset of twitching occurs at postnatal day 16 [156]; interestingly, recent studies have found that the changes in steroidal profile at day 16 in rodents are similar to those featured in adrenarche in primates [158].

Irrespective of mechanistic issues, our preliminary data on finasteride indicate that normalization of neurosteroidogenic alterations in TS may lead to significant therapeutic improvements over currently available therapies, in view of their limited set of side effects. The marked male predominance and high stress sensitivity of TS indicates that silencing the steroid-based mechanisms responsible for these phenomena may yield significant therapeutic benefits; the identification of brain-specific steroidogenic targets may allow us to harness these aspects with limited endocrinological untoward effects.

Acknowledgments

This work was supported by grants from National Institute of Health (R21 HD070611, to M.B.), Tourette Syndrome Association (to M.B. and P.D.), Sardinia Regional Research Grant (to P.D.) and “Master and Back” fellowships (to R.F.). This study was also supported by the National Institute of General Medical Sciences of NIH (P20 GM103638) as well as an NIH Clinical and Translational Science Award grant (UL1 TR000001, formerly UL1RR033179), awarded to the University of Kansas Medical Center. The authors are indebted to the EU COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” for supporting their international collaboration. None of the institutions had any further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

References

1. Albin RL, Mink JW. Recent advances in Tourette syndrome research. *Trends in neurosciences*. 2006; 29(3):175–182. [PubMed: 16430974]
2. Singer HS. Tourette's syndrome: from behaviour to biology. *Lancet neurology*. 2005; 4(3):149–159. [PubMed: 15721825]
3. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-IV-TR*. American Psychiatric Publishing, Inc; 2000.
4. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome Part 1: the epidemiological and prevalence studies. *Journal of psychosomatic research*. 2008; 65(5):461–472. [PubMed: 18940377]
5. Ghanizadeh A, Mosallaei S. Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome. *Brain & development*. 2009; 31(1):15–19. [PubMed: 18558469]
6. Frank MC, Piedad J, Rickards H, Cavanna AE. The role of impulse control disorders in Tourette syndrome: an exploratory study. *Journal of the neurological sciences*. 2011; 310(1–2):276–278. [PubMed: 21741055]
7. Jankovic JT. Tourette syndrome. Phenomenology and classification of tics. *Neurologic clinics*. 1997; 15(2):267–275. [PubMed: 9115460]
8. Jankovic J. Tourette's syndrome. *The New England journal of medicine*. 2001; 345(16):1184–1192. [PubMed: 11642235]

9. Jankovic J. Diagnosis and classification of tics and Tourette syndrome. *Advances in neurology*. 1992; 58:7–14. [PubMed: 1414646]
10. Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. *Movement disorders*. 2003; 18(12):1530–1503. [PubMed: 14673893]
11. Huey ED, Zahn R, Krueger F, Moll J, Kapogiannis D, Wassermann EM, Grafman J. A psychological and neuroanatomical model of obsessive-compulsive disorder. *The Journal of neuropsychiatry and clinical neurosciences*. 2008; 20(4):390–408. [PubMed: 19196924]
12. Robertson MM. Gilles de la Tourette syndrome: the complexities of phenotype and treatment. *British journal of hospital medicine*. 2011; 72(2):100–107. [PubMed: 21378617]
13. Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, Kim YS, Peterson BS. Course of tic severity in Tourette syndrome: the first two decades. *Pediatrics*. 1998; 102(1 Pt 1):14–19. [PubMed: 9651407]
14. Singer HS, Walkup JT. Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment. *Medicine*. 1991; 70(1):15–32. [PubMed: 1988764]
15. Cohen SC, Leckman JF, Bloch MH. Clinical assessment of Tourette syndrome and tic disorders. *Neuroscience and biobehavioral reviews*. 2012
16. Kalanithi PS, Zheng W, Kataoka Y, DiFiglia M, Grantz H, Saper CB, Schwartz ML, Leckman JF, Vaccarino FM. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102(37):13307–13312. [PubMed: 16131542]
17. Kataoka Y, Kalanithi PS, Grantz H, Schwartz ML, Saper C, Leckman JF, Vaccarino FM. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. *The Journal of comparative neurology*. 2010; 518(3):277–291. [PubMed: 19941350]
18. Mink JW. Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns? *Advances in neurology*. 2001; 85:113–122. [PubMed: 11530421]
19. Leckman JF, Bloch MH, Smith ME, Larabi D, Hampson M. Neurobiological substrates of Tourette's disorder. *Journal of child and adolescent psychopharmacology*. 2010; 20(4):237–247. [PubMed: 20807062]
20. Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Munchau A. Pharmacological treatment of tic disorders and Tourette Syndrome. *Neuropharmacology*. 2013; 68:143–149. [PubMed: 22728760]
21. Shale H, Fahn S, Mayeux R. Tics in a patient with Parkinson's disease. *Movement disorders*. 1986; 1(1):79–83. [PubMed: 3504234]
22. Stern E, Silbersweig DA, Chee KY, Holmes A, Robertson MM, Trimble M, Frith CD, Frackowiak RS, Dolan RJ. A functional neuroanatomy of tics in Tourette syndrome. *Archives of general psychiatry*. 2000; 57(8):741–748. [PubMed: 10920461]
23. Minzer K, Lee O, Hong JJ, Singer HS. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum. *Journal of the neurological sciences*. 2004; 219(1–2):55–61. [PubMed: 15050438]
24. Gilbert DL, Christian BT, Gelfand MJ, Shi B, Mantil J, Sallee FR. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. *Neurology*. 2006; 67(9):1695–1697. [PubMed: 17101911]
25. Steeves TD, Ko JH, Kideckel DM, Rusjan P, Houle S, Sandor P, Lang AE, Strafella AP. Extrastriatal dopaminergic dysfunction in tourette syndrome. *Annals of neurology*. 2010; 67(2):170–181. [PubMed: 20225192]
26. Buse J, Schoenefeld K, Munchau A, Roessner V. Neuromodulation in Tourette syndrome: Dopamine and beyond. *Neuroscience and biobehavioral reviews*. 2012
27. Wong DF, Brasic JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, Rousset O, Kumar A, Szabo Z, Gjedde A, Grace AA. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. *Neuropsychopharmacology*. 2008; 33(6):1239–1251. [PubMed: 17987065]

28. Gilbert D, Budman C, Singer H, Kurlan R, Kwan R, Chipkin R. Interim Analysis of an Open-Label, Multi-Center Study of Ecopipam, a Dopamine D1 Receptor Antagonist, for Tic Reduction in Adults with Tourette Syndrome. *Neurology*. 2013
29. Berns GS, Sejnowski TJ. A computational model of how the basal ganglia produce sequences. *Journal of cognitive neuroscience*. 1998; 10(1):108–121. [PubMed: 9526086]
30. Suri RE, Schultz W. Learning of sequential movements by neural network model with dopamine-like reinforcement signal. *Experimental brain research*. 1998; 121(3):350–354. [PubMed: 9746140]
31. Swerdlow NR, Karban B, Ploum Y, Sharp R, Geyer MA, Eastvold A. Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an “fMRI-friendly” startle paradigm. *Biol Psychiatry*. 2001; 50(8):578–585. [PubMed: 11690592]
32. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning. *Current opinion in neurobiology*. 2002; 12(2):217–222. [PubMed: 12015240]
33. Seymour B, O'Doherty JP, Dayan P, Koltzenburg M, Jones AK, Dolan RJ, Friston KJ, Frackowiak RS. Temporal difference models describe higher-order learning in humans. *Nature*. 2004; 429(6992):664–667. [PubMed: 15190354]
34. Castellanos F, Giedd J, Hamburger S, Marsh W, Rapoport J. Brain morphometry in Tourette's syndrome The influence of comorbid attention-deficit/hyperactivity disorder. *Neurology*. 1996; 47(6):1581–1583. [PubMed: 8960751]
35. Swerdlow NR, Young AB. Neuropathology in Tourette syndrome: an update. *Advances in neurology*. 2001; 85:151–161. [PubMed: 11530425]
36. Marsh R, Alexander GM, Packard MG, Zhu H, Wingard JC, Quackenbush G, Peterson BS. Habit learning in Tourette syndrome: a translational neuroscience approach to a developmental psychopathology. *Archives of general psychiatry*. 2004; 61(12):1259–1268. [PubMed: 15583117]
37. Palminteri S, Lebreton M, Worbe Y, Hartmann A, Lehericy S, Vidailhet M, Grabi D, Pessiglione M. Dopamine-dependent reinforcement of motor skill learning: evidence from Gilles de la Tourette syndrome. *Brain*. 2011; 134(Pt 8):2287–2301. [PubMed: 21727098]
38. Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. *Nature reviews Neurology*. 2012; 8(4):203–213.
39. Paschou P. The genetic basis of Gilles de la Tourette Syndrome. *Neuroscience and biobehavioral reviews*. 2013
40. Hoekstra PJ, Dietrich A, Edwards MJ, Elamin I, Martino D. Environmental factors in Tourette syndrome. *Neuroscience and biobehavioral reviews*. 2012
41. Kidd KK, Prusoff BA, Cohen DJ. Familial pattern of Gilles de la Tourette syndrome. *Archives of general psychiatry*. 1980; 37(12):1336–1339. [PubMed: 6934712]
42. Pauls DL, Cohen DJ, Heimbuch R, Detlor J, Kidd KK. Familial pattern and transmission of Gilles de la Tourette syndrome and multiple tics. *Archives of general psychiatry*. 1981; 38(10):1091–1093. [PubMed: 6945827]
43. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, Guez DH, Spertus JA, Leckman JF, Dure LS, Kurlan R, Singer HS, Gilbert DL, Farhi A, Louvi A, Lifton RP, Sestan N, State MW. Sequence variants in *SLITRK1* are associated with Tourette's syndrome. *Science*. 2005; 310(5746):317–320. [PubMed: 16224024]
44. Miranda DM, Wigg K, Kabia EM, Feng Y, Sandor P, Barr CL. Association of *SLITRK1* to Gilles de la Tourette Syndrome. *American journal of medical genetics Part B, Neuropsychiatric genetics*. 2009; 150B(4):483–486.
45. Karagiannidis I, Rizzo R, Tarnok Z, Wolanczyk T, Hebebrand J, Nothen MM, Lehmkuhl G, Farkas L, Nagy P, Barta C, Szymanska U, Panteloglou G, Miranda DM, Feng Y, Sandor P, Barr C, TsgeneSee, Paschou P. Replication of association between a *SLITRK1* haplotype and Tourette Syndrome in a large sample of families. *Molecular psychiatry*. 2012; 17(7):665–668. [PubMed: 22083730]
46. Scharf JM, Miller LL, Mathews CA, Ben-Shlomo Y. Prevalence of Tourette syndrome and chronic tics in the population-based Avon longitudinal study of parents and children cohort. *Journal of the*

- American Academy of Child and Adolescent Psychiatry. 2012; 51(2):192–201. e5. [PubMed: 22265365]
47. Tourette Syndrome Association International Consortium for Genetics. Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families. *American journal of human genetics*. 2007; 80(2):265–272. [PubMed: 17304708]
 48. O'Rourke JA, Scharf JM, Yu D, Pauls DL. The genetics of Tourette syndrome: a review. *Journal of psychosomatic research*. 2009; 67(6):533–545. [PubMed: 19913658]
 49. Swain JE, Scahill L, Lombroso PJ, King RA, Leckman JF. Tourette syndrome and tic disorders: a decade of progress. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2007; 46(8):947–968. [PubMed: 17667475]
 50. Bornstein RA, Stefl ME, Hammond L. A survey of Tourette syndrome patients and their families: the 1987 Ohio Tourette Survey. *The Journal of neuropsychiatry and clinical neurosciences*. 1990; 2(3):275–281. [PubMed: 2136086]
 51. Lombroso PJ, Mack G, Scahill L, King RA, Leckman JF. Exacerbation of Gilles de la Tourette's syndrome associated with thermal stress: a family study. *Neurology*. 1991; 41(12):1984–1987. [PubMed: 1745360]
 52. Nelson EC, Pribor EF. A calendar savant with autism and Tourette syndrome. Response to treatment and thoughts on the interrelationships of these conditions. *Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists*. 1993; 5(2):135–140. [PubMed: 8348206]
 53. Silva RR, Munoz DM, Barickman J, Friedhoff AJ. Environmental factors and related fluctuation of symptoms in children and adolescents with Tourette's disorder. *Journal of child psychology and psychiatry, and allied disciplines*. 1995; 36(2):305–312.
 54. Conelea CA, Woods DW. The influence of contextual factors on tic expression in Tourette's syndrome: a review. *Journal of psychosomatic research*. 2008; 65(5):487–496. [PubMed: 18940379]
 55. Conelea CA, Woods DW, Brandt BC. The impact of a stress induction task on tic frequencies in youth with Tourette Syndrome. *Behaviour research and therapy*. 2011; 49(8):492–497. [PubMed: 21658680]
 56. Lin H, Katsoyich L, Ghebremichael M, Findley DB, Grantz H, Lombroso PJ, King RA, Zhang H, Leckman JF. Psychosocial stress predicts future symptom severities in children and adolescents with Tourette syndrome and/or obsessive-compulsive disorder. *Journal of child psychology and psychiatry, and allied disciplines*. 2007; 48(2):157–166.
 57. Saccomani L, Fabiana V, Manuela B, Giambattista R. Tourette syndrome and chronic tics in a sample of children and adolescents. *Brain & development*. 2005; 27(5):349–352. [PubMed: 16023550]
 58. Motlagh MG, Katsoyich L, Thompson N, Lin H, Kim YS, Scahill L, Lombroso PJ, King RA, Peterson BS, Leckman JF. Severe psychosocial stress and heavy cigarette smoking during pregnancy: an examination of the pre- and perinatal risk factors associated with ADHD and Tourette syndrome. *European child & adolescent psychiatry*. 2010; 19(10):755–764. [PubMed: 20532931]
 59. Bos-Veneman NG, Olieman R, Tobiasova Z, Hoekstra PJ, Katsoyich L, Bothwell AL, Leckman JF, Kawikova I. Altered immunoglobulin profiles in children with Tourette syndrome. *Brain, behavior, and immunity*. 2011; 25(3):532–538.
 60. Leckman JF, Dolnansky ES, Hardin MT, Clubb M, Walkup JT, Stevenson J, Pauls DL. Perinatal factors in the expression of Tourette's syndrome: an exploratory study. *Journal of the American Academy of Child and Adolescent Psychiatry*. 1990; 29(2):220–226. [PubMed: 1969861]
 61. Mathews CA, Bimson B, Lowe TL, Herrera LD, Budman CL, Erenberg G, Naarden A, Bruun RD, Freimer NB, Reus VI. Association between maternal smoking and increased symptom severity in Tourette's syndrome. *Am J Psychiatry*. 2006; 163(6):1066–1073. [PubMed: 16741208]
 62. Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. *Am J Psychiatry*. 1998; 155(2):264–271. [PubMed: 9464208]

63. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. *Pediatrics*. 2005; 116(1):56–60. [PubMed: 15995031]
64. Leslie DL, Kozma L, Martin A, Landeros A, Katsovich L, King RA, Leckman JF. Neuropsychiatric disorders associated with streptococcal infection: a case-control study among privately insured children. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2008; 47(10):1166–1172. [PubMed: 18724258]
65. Martino D, Dale RC, Gilbert DL, Giovannoni G, Leckman JF. Immunopathogenic mechanisms in tourette syndrome: A critical review. *Movement disorders*. 2009; 24(9):1267–1279. [PubMed: 19353683]
66. Lin H, Williams KA, Katsovich L, Findley DB, Grantz H, Lombroso PJ, King RA, Bessen DE, Johnson D, Kaplan EL, Landeros-Weisenberger A, Zhang H, Leckman JF. Streptococcal upper respiratory tract infections and psychosocial stress predict future tic and obsessive-compulsive symptom severity in children and adolescents with Tourette syndrome and obsessive-compulsive disorder. *Biol Psychiatry*. 2010; 67(7):684–691. [PubMed: 19833320]
67. Zohar I, Weinstock M. Differential effect of prenatal stress on the expression of corticotrophin-releasing hormone and its receptors in the hypothalamus and amygdala in male and female rats. *Journal of neuroendocrinology*. 2011; 23(4):320–328. [PubMed: 21306450]
68. Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. *Movement disorders*. 2011; 26(6):1149–1156. [PubMed: 21484868]
69. Santangelo SL, Pauls DL, Goldstein JM, Faraone SV, Tsuang MT, Leckman JF. Tourette's syndrome: what are the influences of gender and comorbid obsessive-compulsive disorder? *Journal of the American Academy of Child and Adolescent Psychiatry*. 1994; 33(6):795–804. [PubMed: 8083136]
70. Lichter DG. Female gender is an independent predictor of tic severity in adult Tourette syndrome. *Movement Disorders*. 2008; 23:S146–S147.
71. Baumgardner TL, Singer HS, Denckla MB, Rubin MA, Abrams MT, Colli MJ, Reiss AL. Corpus callosum morphology in children with Tourette syndrome and attention deficit hyperactivity disorder. *Neurology*. 1996; 47(2):477–482. [PubMed: 8757024]
72. Mostofsky SH, Wendlandt J, Cutting L, Denckla MB, Singer HS. Corpus callosum measurements in girls with Tourette syndrome. *Neurology*. 1999; 53(6):1345–1347. [PubMed: 10522898]
73. Fahim C, Yoon U, Das S, Lyttelton O, Chen J, Arnaoutelis R, Rouleau G, Sandor P, Frey K, Brandner C, Evans AC. Somatosensory-motor bodily representation cortical thinning in Tourette: effects of tic severity, age and gender. *Cortex*. 2010; 46(6):750–760. [PubMed: 19733347]
74. Sandyk R, Bamford CR. Deregulation of hypothalamic opioid and luteinizing hormone releasing factor (LHRF) activity and its relevance to Tourette's syndrome. *The International journal of neuroscience*. 1988; 39(3–4):223–224. [PubMed: 3045034]
75. Sandyk R, Bamford CR, Binkiewicz A, Finley PR. Gonadotropin deficiency in Tourette's syndrome: a preliminary communication. *The International journal of neuroscience*. 1988; 42(1–2):121–125. [PubMed: 3145253]
76. Leckman JF, Scahill L. Possible exacerbation of tics by androgenic steroids. *New England Journal of Medicine*. 1990; 322(23):1674. [PubMed: 2342531]
77. Budman CL, Bruun RD, Park KS, Olson ME. Rage attacks in children and adolescents with Tourette's disorder: a pilot study. *The Journal of clinical psychiatry*. 1998; 59(11):576–580. [PubMed: 9862602]
78. Comings DE, Comings BG. A controlled study of Tourette syndrome. II. Conduct. *American journal of human genetics*. 1987; 41(5):742–760. [PubMed: 3479013]
79. Alexander GM, Peterson BS. Testing the prenatal hormone hypothesis of tic-related disorders: gender identity and gender role behavior. *Development and psychopathology*. 2004; 16(2):407–420. [PubMed: 15487603]
80. Peterson AL, Campise RL, Azrin NH. Behavioral and pharmacological treatments for tic and habit disorders: a review. *Journal of developmental and behavioral pediatrics : JDBP*. 1994; 15(6):430–441. [PubMed: 7884015]

81. Peterson BS, Zhang H, Anderson GM, Leckman JF. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. *Journal of clinical psychopharmacology*. 1998; 18(4):324–331. [PubMed: 9690699]
82. Izmir M, Dursun SM. Cyproterone acetate treatment of Tourette's syndrome. *Canadian journal of psychiatry Revue canadienne de psychiatrie*. 1999; 44(7):710–711. [PubMed: 10500878]
83. Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. *Annals of hepatology*. 2011; 10(1):93–98. [PubMed: 21301018]
84. Schwabe MJ, Konkol RJ. Menstrual cycle-related fluctuations of tics in Tourette syndrome. *Pediatric neurology*. 1992; 8(1):43–46. [PubMed: 1558574]
85. Kompoliti K, Goetz CG, Leurgans S, Raman R, Comella CL. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. *Neurology*. 2001; 57(8):1519. [PubMed: 11673608]
86. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. *Reviews in the neurosciences*. 1994; 5(1):27–41. [PubMed: 8019704]
87. Petitclerc M, Bedard PJ, Di Paolo T. Progesterone releases dopamine in male and female rat striatum: a behavioral and microdialysis study. *Progress in neuro-psychopharmacology & biological psychiatry*. 1995; 19(3):491–497. [PubMed: 7624499]
88. Tomas-Camardiel M, Sanchez-Hidalgo MC, Sanchez del Pino MJ, Navarro A, Machado A, Cano J. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. *Neuroscience*. 2002; 109(3):569–584. [PubMed: 11823067]
89. De Souza MM, Pereira MA, Ardenghi JV, Mora TC, Bresciani LF, Yunes RA, Delle Monache F, Cechinel-Filho V. Filicene obtained from *Adiantum cuneatum* interacts with the cholinergic, dopaminergic, glutamatergic, GABAergic, and tachykinergic systems to exert antinociceptive effect in mice. *Pharmacology, biochemistry, and behavior*. 2009; 93(1):40–46.
90. Tye SJ, Miller AD, Blaha CD. Differential corticosteroid receptor regulation of mesoaccumbens dopamine efflux during the peak and nadir of the circadian rhythm: a molecular equilibrium in the midbrain? *Synapse*. 2009; 63(11):982–990. [PubMed: 19598178]
91. Sanchez MG, Bourque M, Morissette M, Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. *CNS neuroscience & therapeutics*. 2010; 16(3):e43–e71. [PubMed: 20557567]
92. Chappell P, Leckman J, Goodman W, Bisette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, Cohen D. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. *Biol Psychiatry*. 1996; 39(9):776–783. [PubMed: 8731518]
93. Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, et al. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. *Neuropsychopharmacology*. 1995; 12(1):73–86. [PubMed: 7766289]
94. Chappell P, Riddle M, Anderson G, Scahill L, Hardin M, Walker D, Cohen D, Leckman J. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. *Biol Psychiatry*. 1994; 36(1):35–43. [PubMed: 8080901]
95. Corbett BA, Mendoza SP, Baym CL, Bunge SA, Levine S. Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome. *Psychoneuroendocrinology*. 2008; 33(6):810–820. [PubMed: 18487023]
96. Sandyk R, Bamford CR. Heightened cortisol response to administration of naloxone in Tourette's syndrome. *The International journal of neuroscience*. 1988; 39(3–4):225–227. [PubMed: 3165969]
97. Dietl T, Kumpfel T, Hinze-Selch D, Trenkwalder C, Lechner C. Exacerbation of tics by prednisolone. *Der Nervenarzt*. 1998; 69(12):1111–1114. [PubMed: 9888149]
98. Imperato A, Puglisi-Allegra S, Casolini P, Zocchi A, Angelucci L. Stress-induced enhancement of dopamine and acetylcholine release in limbic structures: role of corticosterone. *European journal of pharmacology*. 1989; 165(2–3):337–338. [PubMed: 2776836]

99. Piazza PV, Rougé-Pont F, Deroche V, Maccari S, Simon H, Le Moal M. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. *Proceedings of the National Academy of Sciences*. 1996; 93(16):8716–8720.
100. Mensah-Nyagan AG, Kibaly C, Schaeffer V, Venard C, Meyer L, Patte-Mensah C. Endogenous steroid production in the spinal cord and potential involvement in neuropathic pain modulation. *Journal of Steroid Biochemistry and Molecular Biology*. 2008; 109(3–5):286–293. [PubMed: 18434133]
101. Mensah-Nyagan AG, Do-Régo JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. Regulation of neurosteroid biosynthesis in the frog diencephalon by GABA and endozepines. *Hormones and Behavior*. 2001; 40(2):218–225. [PubMed: 11534986]
102. Paba S, Frau R, Godar SC, Devoto P, Marrosu F, Bortolato M. Steroid 5alpha-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. *Current pharmaceutical design*. 2011; 17(2):151–167. [PubMed: 21361868]
103. Barbaccia ML. Much excitement about antidepressants, DBI and c-FOS. *Pharmacological research : the official journal of the Italian Pharmacological Society*. 2011; 64(4):333–335. [PubMed: 21683143]
104. Sarkar J, Wakefield S, MacKenzie G, Moss SJ, Maguire J. Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2011; 31(50):18198–18210. [PubMed: 22171026]
105. Castelli MP, Casti A, Casu A, Frau R, Bortolato M, Spiga S, Ennas MG. Regional distribution of 5alpha-reductase type 2 in the adult rat brain: an immunohistochemical analysis. *Psychoneuroendocrinology*. 2013; 38(2):281–293. [PubMed: 22776423]
106. Sanchez P, Torres JM, Castro B, Olmo A, del Moral RG, Ortega E. Expression of steroid 5alpha-reductase isozymes in prostate of adult rats after environmental stress. *The FEBS journal*. 2013; 280(1):93–101. [PubMed: 23122426]
107. Bortolato M, Frau R, Orru M, Bourov Y, Marrosu F, Mereu G, Devoto P, Gessa GL. Antipsychotic-like properties of 5-alpha-reductase inhibitors. *Neuropsychopharmacology*. 2008; 33(13):3146–3156. [PubMed: 18354385]
108. Swerdlow NR, Sutherland AN. Preclinical models relevant to Tourette syndrome. *Advances in neurology*. 2006; 99:69–88. [PubMed: 16536353]
109. Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. *Biol Psychiatry*. 1996; 39(1):33–41. [PubMed: 8719124]
110. Cohen AJ, Leckman JF. Sensory phenomena associated with Gilles de la Tourette's syndrome. *The Journal of clinical psychiatry*. 1992; 53(9):319–323. [PubMed: 1517194]
111. Leckman JF, Peterson BS. The pathogenesis of Tourette's syndrome: epigenetic factors active in early CNS development. *Biol Psychiatry*. 1993; 34(7):425–427. [PubMed: 8268326]
112. Miguel EC, Baer L, Coffey BJ, Rauch SL, Savage CR, O'Sullivan RL, Phillips K, Moretti C, Leckman JF, Jenike MA. Phenomenological differences appearing with repetitive behaviours in obsessive-compulsive disorder and Gilles de la Tourette's syndrome. *The British journal of psychiatry*. 1997; 170:140–145. [PubMed: 9093502]
113. Miguel EC, do Rosario-Campos MC, Prado HS, do Valle R, Rauch SL, Coffey BJ, Baer L, Savage CR, O'Sullivan RL, Jenike MA, Leckman JF. Sensory phenomena in obsessive-compulsive disorder and Tourette's disorder. *The Journal of clinical psychiatry*. 2000; 61(2):150–156. quiz 7. [PubMed: 10732667]
114. Devoto P, Frau R, Bini V, Pillolla G, Saba P, Flore G, Corona M, Marrosu F, Bortolato M. Inhibition of 5alpha-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation. *Psychoneuroendocrinology*. 2012; 37(10):1630–1645. [PubMed: 22029952]
115. Frau R, Pillolla G, Bini V, Tambaro S, Devoto P, Bortolato M. Inhibition of 5alpha-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice. *Psychoneuroendocrinology*. 2013; 38(4):542–551. [PubMed: 22877998]

116. Bortolato M, Muroi A, Marrosu F. Treatment of Tourette's syndrome with finasteride. *Am J Psychiatry*. 2007; 164(12):1914–1915. [PubMed: 18056252]
117. Muroi A, Paba S, Puligheddu M, Marrosu F, Bortolato M. A preliminary study of finasteride in Tourette syndrome. *Movement disorders*. 2011; 26(11):2146–2147. [PubMed: 21618612]
118. Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. Finasteride attenuates pathological gambling in patients with Parkinson disease. *Journal of clinical psychopharmacology*. 2012; 32(3):424–425. [PubMed: 22534502]
119. Morissette J, Durocher F, Leblanc JF, Normand T, Labrie F, Simard J. Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22. *Cytogenetics and cell genetics*. 1996; 73(4):304–307. [PubMed: 8751382]
120. Barr CL, Wigg KG, Pakstis AJ, Kurlan R, Pauls D, Kidd KK, Tsui LC, Sandor P. Genome scan for linkage to Gilles de la Tourette syndrome. *American journal of medical genetics*. 1999; 88(4): 437–445. [PubMed: 10402514]
121. Curtis D, Brett P, Dearlove AM, McQuillin A, Kalsi G, Robertson MM, Gurling HM. Genome scan of Tourette syndrome in a single large pedigree shows some support for linkage to regions of chromosomes 5, 10 and 13. *Psychiatric genetics*. 2004; 14(2):83–87. [PubMed: 15167693]
122. Schmidtova E, Kelemenova S, Celec P, Ficek A, Ostatnikova D. Polymorphisms in genes involved in testosterone metabolism in Slovak autistic boys. *The Endocrinologist*. 2010; 20(5): 245–249.
123. Steen NE, Tesli M, Kahler AK, Methlie P, Hope S, Barrett EA, Larsson S, Mork E, Lovas K, Rossberg JI, Agartz I, Melle I, Djurovic S, Lorentzen S, Berg JP, Andreassen OA. SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders. *Progress in neuro-psychopharmacology & biological psychiatry*. 2010; 34(8):1500–1506. [PubMed: 20800085]
124. Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, Mork E, Almas B, Lovas K, Agartz I, Melle I, Berg JP, Andreassen OA. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? *The Journal of clinical psychiatry*. 2011; 72(11):1515–1521. [PubMed: 21367348]
125. Mapes S, Corbin CJ, Tarantal A, Conley A. The primate adrenal zona reticularis is defined by expression of cytochrome b5, 17alpha-hydroxylase/17,20-lyase cytochrome P450 (P450c17) and NADPH-cytochrome P450 reductase (reductase) but not 3beta-hydroxysteroid dehydrogenase/delta5-4 isomerase (3beta-HSD). *The Journal of clinical endocrinology and metabolism*. 1999; 84(9):3382–3385. [PubMed: 10487714]
126. Katagiri M, Kagawa N, Waterman MR. The role of cytochrome b5 in the biosynthesis of androgens by human P450c17. *Arch Biochem Biophys*. 1995; 317(2):343–347. [PubMed: 7893148]
127. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. *Proceedings of the National Academy of Sciences of the United States of America*. 1995; 92(23): 10619–10623. [PubMed: 7479852]
128. Auchus RJ, Lee TC, Miller WL. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. *The Journal of biological chemistry*. 1998; 273(6): 3158–3165. [PubMed: 9452426]
129. Geller DH, Auchus RJ, Miller WL. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. *Mol Endocrinol*. 1999; 13(1):167–175. [PubMed: 9892022]
130. Biason-Lauber A, Kempken B, Werder E, Forest MG, Einaudi S, Ranke MB, Matsuo N, Brunelli V, Schonle EJ, Zachmann M. 17alpha-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation. *The Journal of clinical endocrinology and metabolism*. 2000; 85(3):1226–1231. [PubMed: 10720067]
131. Pattison JC, Saltzman W, Abbott DH, Hogan BK, Nguyen AD, Husen B, Einspanier A, Conley AJ, Bird IM. Gender and gonadal status differences in zona reticularis expression in marmoset monkey adrenals: Cytochrome b5 localization with respect to cytochrome P450 17,20-lyase activity. *Molecular and cellular endocrinology*. 2007; 265–266:93–101.

132. Nguyen AD, Corbin CJ, Pattison JC, Bird IM, Conley AJ. The developmental increase in adrenocortical 17,20-lyase activity (biochemical adrenarche) is driven primarily by increasing cytochrome b5 in neonatal rhesus macaques. *Endocrinology*. 2009; 150(4):1748–1756. [PubMed: 19036885]
133. Auchus RJ, Rainey WE. Adrenarche - physiology, biochemistry and human disease. *Clin Endocrinol (Oxf)*. 2004; 60(3):288–296. [PubMed: 15008992]
134. Fluck CE, Miller WL, Auchus RJ. The 17, 20-lyase activity of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway. *The Journal of clinical endocrinology and metabolism*. 2003; 88(8):3762–3766. [PubMed: 12915666]
135. Gupta MK, Guryev OL, Auchus RJ. 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. *Arch Biochem Biophys*. 2003; 418(2):151–160. [PubMed: 14522586]
136. Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. *Seminars in reproductive medicine*. 2004; 22(4):281–288. [PubMed: 15635496]
137. Kamrath C, Hartmann MF, Remer T, Wudy SA. The activities of 5alpha-reductase and 17,20-lyase determine the direction through androgen synthesis pathways in patients with 21-hydroxylase deficiency. *Steroids*. 2012; 77(13):1391–1397. [PubMed: 22951291]
138. Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA. Increased activation of the alternative “backdoor” pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. *The Journal of clinical endocrinology and metabolism*. 2012; 97(3):E367–E375. [PubMed: 22170725]
139. Eckstein B, Borut A, Cohen S. Metabolic pathways for androstanediol formation in immature rat testis microsomes. *Biochimica et biophysica acta*. 1987; 924(1):1–6. [PubMed: 3828389]
140. Mueller SC, Ng P, Sinaii N, Leschek EW, Green-Golan L, VanRyzin C, Ernst M, Merke DP. Psychiatric characterization of children with genetic causes of hyperandrogenism. *European Journal of Endocrinology*. 2010; 163(5):801–810. [PubMed: 20807778]
141. Yu L, Romero DG, Gomez-Sanchez CE, Gomez-Sanchez EP. Steroidogenic enzyme gene expression in the human brain. *Molecular and cellular endocrinology*. 2002; 190(1–2):9–17. [PubMed: 11997174]
142. Stoffel-Wagner B, Watzka M, Steckelbroeck S, Schramm J, Bidlingmaier JF, Klingmuller D. Expression of 17beta-hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe. *The Journal of endocrinology*. 1999; 160(1):119–126. [PubMed: 9854183]
143. Steckelbroeck S, Watzka M, Reissinger A, Wegener-Toper P, Bidlingmaier F, Bliesener N, Hans VH, Clusmann H, Ludwig M, Siekmann L, Klingmuller D. Characterisation of estrogenic 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity in the human brain. *The Journal of steroid biochemistry and molecular biology*. 2003; 86(1):79–92. [PubMed: 12943747]
144. Compagnone NA, Bulfone A, Rubenstein JL, Mellon SH. Steroidogenic enzyme P450c17 is expressed in the embryonic central nervous system. *Endocrinology*. 1995; 136(11):5212–5223. [PubMed: 7588260]
145. Pelletier G, Luu-The V, Labrie F. Immunocytochemical localization of type I 17 beta-hydroxysteroid dehydrogenase in the rat brain. *Brain Res*. 1995; 704(2):233–239. [PubMed: 8788919]
146. Mensah-Nyagan AM, Feuilloley M, Do-Rego JL, Marcual A, Lange C, Tonon MC, Pelletier G, Vaudry H. Localization of 17beta-hydroxysteroid dehydrogenase and characterization of testosterone in the brain of the male frog. *Proceedings of the National Academy of Sciences of the United States of America*. 1996; 93(4):1423–1428. [PubMed: 8643647]
147. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. *Endocrinology*. 1999; 140(8):3843–3852. [PubMed: 10433246]
148. Matsunaga M, Ukena K, Tsutsui K. Expression and localization of cytochrome P450 17 alpha-hydroxylase/c17,20-lyase in the avian brain. *Brain Res*. 2001; 899(1–2):112–122. [PubMed: 11311872]
149. Halm S, Kwon JY, Rand-Weaver M, Sumpter JP, Pounds N, Hutchinson TH, Tyler CR. Cloning and gene expression of P450 17alpha-hydroxylase,17,20-lyase cDNA in the gonads and brain of the fathead minnow *Pimephales promelas*. *General and comparative endocrinology*. 2003; 130(3):256–266. [PubMed: 12606268]

150. Ogundare M, Theofilopoulos S, Lockhart A, Hall LJ, Arenas E, Sjovall J, Brenton AG, Wang Y, Griffiths WJ. Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain? *The Journal of biological chemistry*. 2010; 285(7):4666–4679. [PubMed: 19996111]
151. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5 α -reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. *Journal of sexual medicine*. 2011; 8(3):872–884. [PubMed: 21176115]
152. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. *Journal of sexual medicine*. 2011; 8(6):1747–1753. [PubMed: 21418145]
153. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. *Journal of clinical psychiatry*. 2012; 73(9):1220–1223. [PubMed: 22939118]
154. Burton FH, Hasel KW, Bloom FE, Sutcliffe JG. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. *Nature*. 1991; 350(6313):74–77. [PubMed: 1848356]
155. Campbell KM, de Lecea L, Severynse DM, Caron MG, McGrath MJ, Sparber SB, Sun LY, Burton FH. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. *The Journal of*. 1999; 19(12):5044–5053.
156. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. *Molecular psychiatry*. 2002; 7(6):617–625. 524. [PubMed: 12140785]
157. McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. *Brain Res*. 2000; 877(1):23–30. [PubMed: 10980239]
158. Pignatelli D, Xiao F, Gouveia AM, Ferreira JG, Vinson GP. Adrenarche in the rat. *The Journal of endocrinology*. 2006; 191(1):301–308. [PubMed: 17065412]
159. Comings DE, Wu S, Chiu C, Ring RH, Gade R, Ahn C, MacMurray JP, Dietz G, Muhleman D. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes--DRD2, D beta H, and DAT1. *American journal of medical genetics*. 1996; 67(3):264–288. [PubMed: 8725745]
160. Diaz-Anzaldúa A, Joobar R, Riviere JB, Dion Y, Lesperance P, Richer F, Chouinard S, Rouleau GA, Montreal Tourette Syndrome Study G. Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder population. *Molecular psychiatry*. 2004; 9(3):272–277. [PubMed: 15094788]
161. Tarnok Z, Ronai Z, Gervai J, Kereszturi E, Gadoros J, Sasvari-Szekely M, Nemoda Z. Dopaminergic candidate genes in Tourette syndrome: association between tic severity and 3' UTR polymorphism of the dopamine transporter gene. *American journal of medical genetics Part B, Neuropsychiatric genetics*. 2007; 144B(7):900–905.
162. Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O'Roak BJ, Mason CE, Abbott T, Gupta A, King RA, Pauls DL, Tischfield JA, Heiman GA, Singer HS, Gilbert DL, Hoekstra PJ, Morgan TM, Loring E, Yasuno K, Fernandez T, Sanders S, Louvi A, Cho JH, Mane S, Colangelo CM, Biederer T, Lifton RP, Gunel M, State MW. L-histidine decarboxylase and Tourette's syndrome. *The New England journal of medicine*. 2010; 362(20):1901–1908. [PubMed: 20445167]
163. Lawson-Yuen A, Saldivar JS, Sommer S, Picker J. Familial deletion within NLGN4 associated with autism and Tourette syndrome. *European journal of human genetics : EJHG*. 2008; 16(5): 614–618. [PubMed: 18231125]
164. Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA, Tourette Syndrome Association International Consortium for G. CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. *Genomics*. 2003; 82(1):1–9. [PubMed: 12809671]
165. Boghosian-Sell L, Comings DE, Overhauser J. Tourette syndrome in a pedigree with a 7;18 translocation: identification of a YAC spanning the translocation breakpoint at 18q22.3. *American journal of human genetics*. 1996; 59(5):999–1005. [PubMed: 8900226]




Fig. 1. Schematization of major neurosteroidogenic pathways. Metabolic changes in steroid configurations are represented in the same color as the enzymes (boxes) catalyzing the reactions. Red arrows represent the major reactions corresponding to the “backdoor” pathway of DHT synthesis. Dotted arrows represent reactions that have been hypothesized, but not fully ascertained in the brain. Enzymes: 3 β -HSD: 3 β -hydroxysteroid dehydrogenase; 5 α R, 5 α -reductase 17 β -HSD: 17 β -hydroxysteroid dehydrogenase; 3 α -HSOR: 3 α -hydroxysteroid oxidoreductase; CYP21A2: Steroid 21-hydroxylase; CYP17A1: cytochrome P450 17A1. Steroids: DOC, deoxycorticosterone; 5 α -DHDOC, 5 α -dihydro deoxycorticosterone; 3 α ,5 α -THDOC, 3 α ,5 α -tetrahydrodeoxycorticosterone; 3S-pregnenolone, pregnenolone sulfate; DHP, 5 α -dihydroprogesterone; AP, 3 α ,5 α -tetrahydroprogesterone (allopregnanolone); 17-OH-Preg, 17-hydroxypregnenolone; 17-OH-Prog, 17-hydroxyprogesterone; 17-OH-DHP, 17-hydroxydihydroprogesterone; 17-OH-AP,

17-hydroxyallopregnanolone; 3-S DHEA dehydroepiandrosterone sulfate; DHEA, dehydroepiandrosterone; 3S- androstenediol, androstenediol sulfate; DHT, 5 α -dihydrotestosterone; 3 α -diol, 5 α -androstane-3 α ,17 β -diol.




Fig. 2. Effects of finasteride (FIN) on severity of tics in patients with Tourette syndrome (n=16). FIN induced significant reductions in the severity of (A) global symptoms [$X^2(4)=48.41$, $P<0.001$], (B) total tics [$X^2(4)=51.07$, $P<0.001$], (C) motor tics [$X^2(4)=50.03$, $P<0.001$], and (D) phonic tics [$X^2(4)=47.31$, $P<0.001$], as assessed by Yale Global Tic Severity Scale (YGTSS) scores (after adjustment for multiple comparisons). *, $P<0.05$; ***, $P<0.001$ versus baseline scores (week 0). Analyses of YGTSS scores were performed with Friedman's test, followed by Wilcoxon-Nemenyi-McDonald-Thompson test for *post-hoc* comparisons.

Table 1

List of the key genes heretofore implicated in Tourette syndrome and their chromosomal locations.

Gene	Location	References
<i>DAT1</i>	5p15.3	[159–161]
<i>MAOA</i>	Xp11.3	[160]
<i>SLITRK1</i>	13q31.1	[43–45]
<i>HDC</i>	15q21-q22	[162]
<i>NLGN4</i>	Xp22.33	[163]
<i>CNTNAP2</i>	7q35	[164]
<i>IMMP2L</i>	7q31	[165]